Timeline / 2 linked reports
FDA proposes easier access to unproven peptide drugs
This timeline contains reports linked by the NOISE desk. Automatic links follow a check of each report and its sources. It does not include all coverage of the subject.
-
Report 1
FDA proposes easier access to unproven peptide drugs
The FDA has submitted an "Interim Access Policy" on peptide drugs for White House review under Health Secretary Robert F. Kennedy Jr. According to the Associated Press, the policy would grant "enforcement discretion," allowing the agency to decline enforcement of restrictions on certain peptides and reassure specialty pharmacies making them. In 2023, FDA scientists found the peptides lack safety and efficacy data and pose risks, and removed them from the compounding list; the agency is now re-reviewing 12 of the drugs after a panel weighted with new members tied to peptide businesses recommended restoring six. Advocacy group CSPI has urged acting FDA Commissioner Kyle Diamantas to disregard the recommendations, warning consumers face risk of serious injury from unsupported claims, while formal rulemaking to restore the peptides could take years, making enforcement discretion a faster path to access.
From Evening NOISE.
-
Report 2
RFK Jr. overrules FDA to allow six peptide sales
Health and Human Services Secretary Robert F. Kennedy Jr. unilaterally issued a rule letting compounding pharmacies sell six unproven peptides, overriding the Food and Drug Administration's safety concerns. The policy, scheduled for publication Oct. 30, covers BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The rule follows Kennedy's appointment of eight new FDA advisory panel members, at least six with ties to peptide businesses. Critics say the untested products pose safety risks and could reduce incentives for clinical trials.
From Morning NOISE.